| Code | Description | Claims | Beneficiaries | Total Paid |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
34,595 |
15,830 |
$2.09M |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
22,231 |
9,923 |
$343K |
| G2024 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source |
16,290 |
6,910 |
$300K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
16,315 |
8,537 |
$273K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,597 |
2,008 |
$159K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
37 |
36 |
$7K |
| 86769 |
|
46 |
45 |
$1K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
12 |
12 |
$600.00 |
| 80053 |
Comprehensive metabolic panel |
54 |
53 |
$45.86 |
| 80061 |
Lipid panel |
38 |
38 |
$45.80 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
60 |
59 |
$33.54 |
| 84443 |
Thyroid stimulating hormone (TSH) |
38 |
38 |
$29.22 |
| 36415 |
Collection of venous blood by venipuncture |
15 |
14 |
$0.00 |